Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 16 Issue 12, December 2017

Comment

  • The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.

    • Ferran Sanz
    • François Pognan
    • Ismael Zamora
    Comment

    Advertisement

Top of page ⤴

News and Analysis

  • Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.

    • Asher Mullard
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

An Audience With

  • Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.

    An Audience With
Top of page ⤴

From the Analyst's Couch

  • This article discusses investment in microbiome-based therapeutic approaches and key questions for the field related to the underlying science, clinical development, regulation and business models.

    • Pedro M. Valencia
    • Magali Richard
    • Elsy Boglioli
    From the Analyst's Couch
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Research Highlight

Top of page ⤴

Analysis

  • G protein-coupled receptors (GPCRs) are the most intensively studied class of drug targets. This article presents a pioneering analysis of all GPCR-targeted drugs and agents that are currently in clinical trials, and discusses the trends across molecule types, drug targets and therapeutic indications.

    • Alexander S. Hauser
    • Misty M. Attwood
    • David E. Gloriam
    Analysis
Top of page ⤴

Review Article

  • Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases.

    • Daniella M. Schwartz
    • Yuka Kanno
    • John J. O'Shea
    Review Article
  • Aggregates of the microtubule-associated protein tau are a defining feature of several neurodegenerative disorders, including Alzheimer disease (AD). Given the recent failures of several amyloid-β-targeted therapies for AD, interest is growing in tau as an alternative target, and this Review describes preclinical and clinical studies of tau-based approaches in the light of recent advances in the understanding of the physiological and pathological roles of tau.

    • Chuanzhou Li
    • Jürgen Götz
    Review Article
Top of page ⤴

Search

Quick links